136 PLWH that switched therapy into DTG/RPV or DTG/3TC regimens were enrolled, some data are missing because some patients changed therapy or were not punctual at follow-up. At week 48 98,7% (IC 92.8%-99.9%) had virological control in the per-protocol analysis. All patients had HIV-RNA lower than 200copies/ml. Between baseline and week 24 we observed an increase in creatinine values and a decrease in eGFR with adjusted p-value 0,0074. These alterations remained within the normal range and were not significantly confirmed comparing week 48 with week 24 and baseline. There were not clinically significant differences on CD4+ T-cell count, metabolic profile and liver function indices. Conclusions: Dual therapy based on DTG is effective and safe. A small decrease in renal function at week 24 is registered but it is not confirmed at week 48. General conditions 1. I confirm that I previewed this abstract and that all information is correct. I accept that the content of this abstract cannot be modified or corrected after the submission deadline and I am aware that it will be published exactly as submitted.: Yes 2. I confirm that the submission of the abstract constitutes my consent to publication (e.g. conference website, programmes, other promotions, etc.). : Yes 3. I herewith confirm that the contact details saved in this system are those of the corresponding author, who will be notified about the status of the abstract. The corresponding author is responsible for informing the other authors about the status of the abstract.: Yes 4. I agree that all data provided may be used (saved, stored, processed, transmitted and deleted) in compliance with the privacy policy to provide the services described.: Yes 189
RkJQdWJsaXNoZXIy Mzc2ODc=